Lutter Michael
Eating Recovery Center of Dallas, 4716 Alliance Blvd. #400, Plano, TX, 75093, USA.
Neurotherapeutics. 2017 Jul;14(3):614-622. doi: 10.1007/s13311-017-0535-x.
Eating disorders (EDs), including anorexia nervosa, bulimia nervosa, and binge-eating disorder, constitute a class of common and deadly psychiatric disorders. While numerous studies in humans highlight the important role of neurobiological alterations in the development of ED-related behaviors, the precise neural substrate that mediates this risk is unknown. Historically, pharmacological interventions have played a limited role in the treatment of eating disorders, typically providing symptomatic relief of comorbid psychiatric issues, like depression and anxiety, in support of the standard nutritional and psychological treatments. To date there are no Food and Drug Administration-approved medications or procedures for anorexia nervosa, and only one Food and Drug Administration-approved medication each for bulimia nervosa (fluoxetine) and binge-eating disorder (lisdexamfetamine). While there is little primary interest in drug development for eating disorders, postmarket monitoring of medications and procedures approved for other indications has identified several novel treatment options for patients with eating disorders. In this review, I utilize searches of the PubMed and ClinicalTrials.gov databases to highlight emerging treatments in eating disorders.
饮食失调（EDs），包括神经性厌食症、神经性贪食症和暴饮暴食症，是一类常见且致命的精神疾病。虽然众多针对人类的研究强调了神经生物学改变在饮食失调相关行为发展中的重要作用，但介导这种风险的确切神经基质尚不清楚。从历史上看，药物干预在饮食失调治疗中发挥的作用有限，通常只是为支持标准的营养和心理治疗，对共病的精神问题（如抑郁和焦虑）提供症状缓解。迄今为止，美国食品药品监督管理局（FDA）尚未批准用于治疗神经性厌食症的药物或程序，对于神经性贪食症（氟西汀）和暴饮暴食症（赖右苯丙胺），FDA仅各批准了一种药物。虽然对饮食失调药物研发的主要兴趣不大，但对已批准用于其他适应症的药物和程序进行上市后监测，已为饮食失调患者确定了几种新的治疗选择。在本综述中，我通过检索PubMed和ClinicalTrials.gov数据库，来突出饮食失调的新兴治疗方法。
